PHARMATECA » Search Articles by Keyword
Found: 8 articles
Article |
Edition |
V.I. Petrov, O.V. Shatalova, M.S. Klykova, N.P. Stetsky
The use of sodium-glucose co-transporter type II (SGLT2) inhibitors in patients with chronic heart failure against the background of type 2 diabetes mellitus
|
№12 / 2023
|
A.E. Bagriy, O.A. Prikolota, A.V. Prikolota, E.S. Mikhailichenko, I.A. Golodnikov, O.N. Bagriy, K.A. Kotova
Clinical effects of dapagliflozin in patients with type 2 diabetes mellitus and paroxysmal atrial fibrillation
|
№11-12 / 2022
|
M.B. Antsiferov (1), O.M. Koteshkova (1), M.S. Novikova (1), N.A. Demidov (2)
Possibilities of dapagliflozin in cardio-reno-metabolic protection in patients with and without type 2 diabetes mellitus
|
№12 / 2021
|
L.A. Sharonova, A.F. Verbovoy
The place of glyflozins in the management of type 2 diabetes mellitus
|
№4 / 2019
|
M.B. Antsiferov (1), B.B. Kvasnikov (2)
The first results of an observational retrospective study assessing the effectiveness of the use dapagliflozin in patients with type 2 diabetes mellitus in real clinical practice in the Russian Federation (GLORIA study)
|
№4 / 2019
|
M.B. Antsiferov
FEATURES OF USE OF DAPAGLIFLOZIN IN THETREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
|
№16 / 2016
|
G.R. Galstyan
HYPOGLYCEMIC EFFECTS OF FLOZINES COMPARED TO SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
|
№17 / 2015
|
E.A. Ushkalova
NEW CLASS OF ANTIDIABETIC DRUGS - SODIUM- GLUCOSE COTRANSPORTER INHIBITORS
|
№16 / 2013
|
{"loading":"Loading...","close":"Close","yes":"Yes","no":"No","proceed":"Proceed","conf_del":"Do you really want to delete","cancel":"Cancel"}